<DOC>
	<DOCNO>NCT01325415</DOCNO>
	<brief_summary>The purpose study evaluate effect QTc interval healthy male administer single dose NKTR-118 compare placebo moxifloxacin . ( QTc specific time interval measure heart beat take Electrocardiogram ( ECG ) )</brief_summary>
	<brief_title>A Placebo-controlled Four Way Crossover Study Asses Effect Single Oral Dose NKTR-118 QTc Interval Healthy Male Subjects</brief_title>
	<detailed_description>A Single Center , Randomized , Double-blinded , Placebo-controlled , Open-label , Positive-controlled , Four-way Crossover Study Assess Effect Single Oral Dose NKTR-118 Administration QTc Interval Compared Placebo , Using AVELOX ( moxifloxacin ) Positive Control , Healthy Male Subjects</detailed_description>
	<mesh_term>Naloxegol</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Healthy male subject age 18 50 year ( inclusive ) suitable vein cannulation repeat venipuncture . Body mass index ( BMI ) 18 30 kg/m2 ( inclusive ) weight least 50 kg 100 kg . Clinically significant medical history include severe allergy history mental disorder cardiac history , history presence gastrointestinal , hepatic , renal disease . Abnormal heart rhythm include abnormal arrhythmia , mark sinus arrhythmia , junctional rhythm . Known suspected history drug abuse , current smoker smoke and/or use nicotine product within 3 month prior enrollment . Excessive intake caffeinecontaining product</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>healthy male volunteer</keyword>
	<keyword>cross-over study</keyword>
	<keyword>NKTR-118</keyword>
</DOC>